CD BioGlyco is committed to building a leading glycogene engineering service. To this end, we specialize in building highly executive and experienced research teams. We have a wide variety of Technologies for Gene Editing. We regulate the expression of glycogene through overexpression, knockdown, knock-in, knockdown, and many other Strategies. Based on our vast experience, we achieve one-stop technical service solutions for gene editing, bioinformatics, pharmacology, efficacy, etc.
Fig.1 One-stop glycogene editing service. (CD BioGlyco)
Fig.2 Advantages for gene editing. (CD BioGlyco)
Glucosyltransferase catalyzes the transfer of glucose from specifically activated donors to specific acceptor molecules. It is a highly diverse group of enzymes. CD BioGlyco affects sugar synthesis by knocking out or overexpressing the glucosyltransferase gene.
Galactosyltransferase belongs to the family of glycosyltransferases, which is classified into B3galts, B4galts, etc. CD BioGlyco has extensive experience in galactosyltransferase gene modification in animals, plants, and microorganisms.
MTase is commonly found in eukaryotes. It affects plant disease resistance and immunity, embryo development, protein glycosylation, cancer cell migration, etc. CD BioGlyco will modify different MT genes according to customers' requirements. We also provide MT heterologous expression service.
GnTs catalyze the synthesis of complex glycans with multiple structures. It has an important role in glycoprotein synthesis. CD BioGlyco investigates the effects of GnT gene modification by constructing various mouse and cell line models.
Polypeptide GALNT is an initiating enzyme that catalyzes the modification of mucin-type O-glycosylation. It affects tumor cell genesis, proliferation, and migration, etc. CD BioGlyco offers a wide range of GALNT gene modification services to help clients investigate its application in disease treatment.
FucT is highly expressed in tumors such as lung cancer and colon cancer. It is associated with various diseases such as atherosclerosis, etc. CD BioGlyco will help clients study the application of FUT3, FUT4, FUT7, and other genes in the treatment of diseases according to their requirements.
ST is an enzyme required for the synthesis of sialylated oligosaccharides. CD BioGlyco provides services such as ST gene editing, enzyme activity assay, mouse disease modeling, and compound testing.
UDP-glucuronyltransferase (UGT) is a microsomal glycosyltransferase that is associated with a variety of diseases. Its encoding gene, UGT, is a supergene family that encodes several isoenzymes. CD BioGlyco edits multiple UGT genes to validate UGT function and applications in drug metabolism.
The Gag gene encodes a protein that produces many HIV-1 CTL antigenic epitopes. The polymerase gene encodes an enzyme that produces reverse transcriptase and protease enzymes, among others. CD BioGlyco provides HIV vaccine development and retroviral packaging services.
SULT is a highly conserved class of proteins. It catalyzes the sulphonation of a range of compounds. CD BioGlyco provides gene editing services for SULT of human origin and plant SULT.
CD BioGlyco provides high-quality glycogene engineering transformation services for biological research enterprises, scientific research institutes, etc. In addition, we also provide a Cancer Glycogene Discovery Service. Please feel free to contact us with any questions.